Materials and Methods
Introduction
Efforts to regenerate lost or injured tissue, such as the clinical regeneration of the periodontium, as a therapeutic strategy in those with periodontal defects, is an area of current medical interest. Tissue engineering approaches using stem cells, scaffolds, and signaling molecules were proposed in the 1990s 1) , while guided tissue regeneration and bio-regeneration approaches have been applied to clinical situations 2) . In particular, the application of growth factors, such as bone morphogenetic protein (BMP) 3) , basic fibroblast growth factor (b-FGF) 4) , and platelet-derived growth factor (PDGF) 5) have been investigated for their involvement in periodontal regeneration.
Parathyroid hormone (PTH) is a peptide regulator of calcium and phosphate metabolism. Although continuous exposure to PTH promotes bone resorption by stimulating osteoclast activity, its intermittent administration promotes new bone formation by stimulating osteoblast differentiation 6) . Systemic administration of recombinant human PTH (rhPTH) has been shown to significantly stimulate local bone formation in a rat calvarial defect model 7) , while clinical studies have shown that rhPTH therapy significantly increases spine bone mineral density (BMD), total hip BMD, and femoral BMD in adults with a mild form of osteogenesis imperfecta 8) . The clinical benefits of rhPTH thus reflect its ability to stimulate bone formation and thereby increase bone mass and strength, and the hormone appears to be effective in preventing fractures in osteoporosis 9, 10) . The application of rhPTH may also be effective for the treatment of oral defects, with reports that intermittent systemic administration of rhPTH is able to protect against periodontitis-associated bone resorption in rodents 11, 12) , and resolve bisphosphonate-associated osteonecrosis of the jaw 13) . However, the effect of local intermittent rhPTH administration is not sufficiently clear. The aim of this study was to evaluate the benefits of local intermittent administration of rhPTH for bone regeneration in rats with cranial bone defects.
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Key words: Bone, Cranial bone defects, Local administration, Parathyroid hormone, Rat mals (n=2) received sham surgery. Following surgery, control, collagen, and PTH-1 animals received subcutaneous injections of saline (0.05 ml) once a week for 2 weeks, while the PTH-3 group received subcutaneous injections of rhPTH (14.1 μg/kg) once a week for 2 weeks. Animals were fed regular chow and sterile water throughout the experimental period, and were euthanized at 3 weeks post-surgery using CO 2 . The calvariae were then removed and fixed in 4% neutral formalin.
Micro-computed tomography assessment
All samples were radiographed using micro-computed tomography (μ-CT) scans (Scanmate-Rb090SS150; Comscan, Yokohama, Japan). The settings for the μ-CT were 74.5 kV, 45.5 mA, and 2.7x magnification. Three-dimensional images were produced using the computer software 3D-BON (RATOC, Tokyo, Japan), and were used to calculate the ratio of new bone mineral content to total defect volume (BMC/TV).
Histochemical preparation
After radiographic analysis, all specimens were demineralized using 10% EDTA, embedded in paraffin, and sectioned at 5 μm thickness. The center of selected defect sections was stained histochemically using hematoxylin and eosin (HE), and immunohistochemically using anti-alkaline phosphatase (ALP) (Rabbit Monoclonal Antibody; Abcam, Woburn, MA), anti-dentin matrix protein 1 (DMP1) (Anti-Dentin Matrix Protein 1 polyclonal antibody; TaKaRa Biomedicals, Shiga, Japan) and anti-Osterix (Rabbit Anti-Osterix Polyclonal Antibody; Bioss, Burlingam, CA) antibodies. Sections were deparaffinized with xylene, and were immersed into descending grades of ethanol from 100% to 95%, and 3% H 2 O 2 included methanol was used to block endogenous peroxidase activity. After blocking, each primary antibody was allowed to react overnight at 4°C, and secondary antibodies (simple stain mouse MAX-PO(R), Nichirei Bioscience, Tokyo, Japan) were used for detection of primary antibodies. For visualization of reactive products, diaminobenzidine (ImmPACT TM DAB; Vector Laboratories, Burlingame, CA) was used as a chromogen substrate, followed by counterstaining with hematoxylin. Using imaging software (Image J), histomorphology was analyzed in HE sections, with the area of new bone formation (N) to the area of defect (D) expressed as a percentage (N/D%)
Statistical analysis
The BMC/TV ratio and N/D% were evaluated using Scheffe's test to determine differences between groups, with p < 0.05 considered statically significant. All values are expressed as means ± standard deviation. 
Results

Micro-CT analyses of bone regeneration
Representative μ-CT radiographs are shown in Fig. 1 , with the quantitation of BMC/TV ratios shown in Fig. 2 (control group, 981.6 ± 37.0 mg/cm 3 ; collagen group, 786.3 ± 61.7 mg/cm 3 ; PTH-1 group, 1154.0 ± 107.1 mg/cm 3 ; PTH-3 group, 1218.0 ± 59.2 mg/cm 3 ). The PTH-3 and PTH-1 groups had significantly greater BMC/TV ratios than the collagen group (p < 0.05; Fig. 2 ).
Histological observations
Photomicrographs of representative HE-stained sections are shown in Fig. 3 , and the N/D% for the different groups is shown in Fig. 4 . The N/D% was 20.6 ± 1.1% in controls, 33.1 ± 3.7% in the collagen group, 40.3 ± 9.6% in the PTH-1 group, and 42.0 ± 2.5% in the PTH-3 group. The PTH-3 animals had a significantly higher N/D% when compared to controls.
Immunohistochemistry
ALP-positive immunostaining was associated with osteoblasts ( Fig.  5) , with ALP-positive osteoblasts present at the new bone surface of all groups. DMP1 expression was intense in the regions surrounding osteocytes ( Fig. 6) , with PTH-3 animals having greater numbers of DMP1-positive cells than the other groups. Finally, Osterix-positive osteoblasts were present at the new bone surface in the connective tissue ( Fig. 7) . Many Osterix-positive osteoblasts were observed in the samples from the PTH-3 and PTH-1 groups, but there were few in the samples from the collagen and control groups.
Discussion
In this study, we evaluated the effects of local administration of rhPTH for bone regeneration in rats with cranial bone defects. We created 4.3-mm diameter cranial osteotomy defects, because 3-mm diameter cranial osteotomy defects do not fully close for 3 weeks 14) . The intermittent PTH schedule and dose used in the present study were based on previous studies by Eduardo-de-Paula et al 15) . Previous work has shown that rhBMP-4 delivered with an ACS in this rat calvarial defect model results in partial ACS resorption and new bone formation at 2 weeks, but at 8 weeks, the ACS is completely resorbed and defects are almost completely filled with lamellar bone 16) . In the present study, an ACS was used as a scaffold in the collagen, PTH-1, and PTH-3 groups, and at 3 weeks post-surgery, the ACS partially remained. The collagen group showed a lower BMC/TV ratio than the control group, indicating that the ACS might inhibit new bone formation.
PTH is an 84-amino acid polypeptide, with the active component consisting of the 34 amino acids from the N-terminus. This shorter peptide forms the basis of the rhPTH teriparatide. In our study, anti-ALP and anti-Osterix immunostaining revealed osteoblasts at the new bone surface. Teresita et al. reported that intermittent administration of rhPTH attenuates osteoblast apoptosis, thereby increasing osteoblast number, the rate of bone formation, and bone mass [17] [18] [19] [20] . Intermittent administration of PTH directly acts on osteoblasts to arrest cell cycle progression from G1 to S phase, and increase differentiation 17) . Based on the results of the present study, we suggest that the intermittent administration of rhPTH directly activates osteoblasts, resulting in an increase in osteoblast number, rate of bone formation, differentiation, and bone mass. The transcription factor Osterix is required for osteoblast differentiation, with Osterix-null mice having no bone formation [21] [22] [23] [24] , and rhPTH is essential for expression of this transcription factor 25) . Finally, Yuske et al. reported that the expression of DMP1 is mainly confined to osteocytes 26) . In our study, DMP1 immunostaining was mainly seen in the regions surrounding osteocytes in areas of new bone.
John et al. reported that long-term treatment of rats with rhPTH caused focal bone proliferative lesions, including osteosarcoma 27) . Our findings indicate that local administration of rhPTH enhances bone formation, but we have not verified potential systemic effects. Therefore, further work is required to confirm the optimal rhPTH administration, dose level, and treatment duration at sites of osseous wound healing in order to maximize benefits and minimize systemic effects. In conclusion, local and intermittent administration of rhPTH in rats with cranial bone defects significantly enhanced bone regeneration. Consequently, we suggest that local and intermittent administration of rhPTH is effective for periodontal regeneration.
